Drug Trial Radar · NCT06006104
Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
49
Planned (sponsor's estimate)
Start
Sep 30, 2023
Primary completion
Sep 30, 2024
Study completion Oct 31, 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of HRS-4357 injection in adult patients with advanced prostate cancer.
Conditions
- Advanced Prostate Cancer
Interventions
HRS-4357 injectionDrug
HRS-4357 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prog Dose limiting toxicity (DLT)Time frame: up to 9 months follow-up
- recommended phase 2 dose (RP2D)Time frame: up to 9 months follow-up
- recommended dosing cycle.Time frame: up to 9 months follow-up
- PSA50 response rateTime frame: up to 12 weeks follow-up
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.